跳至主要内容
临床试验/NCT01664052
NCT01664052已完成不适用

ESS505 Pre-hysterectomy Protocol: Safety and Short Term Effectiveness Study

Bayer2 个研究点 分布在 2 个国家目标入组 66 人开始时间: 2012年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
66
试验地点
2
主要终点
Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation

研究概览

简要总结

This study has been designed to evaluate an investigational model of the Essure System for Permanent Birth Control. The investigational device is designed to offer all the advantages of the currently approved device. In addition, the investigational device offers immediate, permanent contraception without a three-month waiting period or 90-day confirmation test. This study has been designed to evaluate the effectiveness of the investigational device in causing tubal occlusion from insert placement through three months of wearing.

详细描述

This study has previously been posted by Conceptus, Inc. (US).

After acquiring Conceptus, Inc., Bayer HealthCare AG (Germany) is the sponsor of the trial.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Subjects who are scheduled to undergo a Laparoscopically Assisted Vaginal Hysterectomy (LAVH), Total Abdominal Hysterectomy (TAH), Total Vaginal Hysterectomy (TVH), Total Laparoscopic Hysterectomy (TLH) with Bilateral Total Salpingectomy or Bilateral Salpingo-oophorectomy (BSO), or Laparoscopic Supracervical Hysterectomy (LSH)
  • Subjects who are 18 years of age and older
  • Subjects who are able and willing to provide written informed consent
  • Subjects who agree to use a contraceptive method following Essure placement until the hysterectomy procedure

排除标准

  • Subjects with bilateral proximal tubal occlusion
  • Subjects who have undergone fallopian tube sterilization
  • Subjects with known endometrial or myometrial pathology which is likely to prevent access to the fallopian tube ostia
  • Subjects who are post-menopausal
  • Subjects with pelvic inflammatory disease (PID)
  • Subjects with gynecologic malignancy
  • Pregnancy or suspected pregnancy
  • Delivery or termination of a pregnancy less than 6 weeks before Essure micro-insert placement
  • Known allergy to contrast media
  • Any general health condition that may represent, in the opinion of the Investigator, an increased potential risk associated with participation

结局指标

主要结局

Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation

时间窗: 60 minutes after insert placement

Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion.

Number of Occluded Fallopian Tubes 30 Days Following Placement as Measured by an HSG Evaluation

时间窗: 30 days after insert placement

Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion. ESS505 and ESS505-A inserts are designed with the addition of an articulated hydrogel plug bonded to the distal portion of the insert with surgical grade adhesive and a nitinol support wire that remains inside the distal inner coil.

Number of Occluded Fallopian Tubes 60 Days Following Placement as Measured by an HSG Evaluation

时间窗: 60 days after insert placement

Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion. ESS505 and ESS505-A inserts are designed with the addition of an articulated hydrogel plug bonded to the distal portion of the insert with surgical grade adhesive and a nitinol support wire that remains inside the distal inner coil.

Number of Occluded Fallopian Tubes 90 Days Following Placement as Measured by an HSG Evaluation

时间窗: 90 days after insert placement

Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion. ESS505 and ESS505-A inserts are designed with the addition of an articulated hydrogel plug bonded to the distal portion of the insert with surgical grade adhesive and a nitinol support wire that remains inside the distal inner coil.

次要结局

未报告次要终点

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验